Clinical Trial: Retrospective analysis of the efficacy and safety of 100 mg abrocitinib in patients with moderate to severe atopic dermatitis: Real-world study (China)

China, Oct. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Retrospective analysis of the efficacy and safety of 100 mg abrocitinib in patients with moderate to severe atopic dermatitis: Real-world study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600134174

Registration Time: 2026/10/12

Type: Observational study

Primary Sponsor: Shenzhen Second People's Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=314275

Published by HT Digital Content Services with permission from Health Daily Digest....